Japanese pharmaceutical giant Takeda announced it will discontinue all cell therapy research and development activities, including platform technologies and clinic-ready programs without active clinical trials. The decision follows a strategic portfolio prioritization aiming to accelerate transformative therapies through biologics, small molecules, and antibody-drug conjugates. Takeda expects an impairment charge near $394 million related to its gamma delta cell therapy technology. The move reflects a broader industry trend amid challenging funding environments.